← All Stocks

Boston Scientific Corporation

BSX · NYQ
$44.62-0.67%
52W Low: $42.2052W High: $105.65
Current: $44.62  ·  4% of 52-week range
HealthcareMedical DevicesNYQ
View live charts, options flow & technicals for Boston Scientific Corporation → Open Dashboard

Boston Scientific Corporation (BSX) is a healthcare company in the medical devices industry with $21.00B in trailing revenue trading at a 18.2× trailing P/E — analyst consensus: buy.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Key Statistics

Market Cap$64.66B
Revenue (TTM)$21.00B
EPS (TTM)$2.45
EPS (Fwd est.)$3.42
Employees59,000
Trailing P/E18.21
Forward P/E13.05
PEG Ratio0.63
Price / Sales3.08
Price / Book2.59
EV / EBITDA13.48
Beta (5Y)0.57

Analyst Consensus

Consensus
Buy
Analyst Price Target
+36.7% upside
Target: $61.00

Annual Revenue & Net Income

RevenueNet Income
'22
$12.68B
$700.00M
'23
$14.24B
$1.59B
'24
$16.75B
$1.85B
'25
$20.07B
$2.90B

Earnings History


QuarterActual EPSEstimateResult
Jul 2026
$0.86
$0.83Beat (+3.9%)
Apr 2026
$0.80
$0.79Beat (+1.6%)
Feb 2026
$0.80
$0.78Beat (+2.4%)
Oct 2025
$0.75
$0.71Beat (+5.1%)

Next Earnings Report

Boston Scientific Corporation is next expected to report earnings on 28 Oct 2026.

Profitability

69.2%
22.9%
17.5%
Gross
Margin
Operating
Margin
Net
Margin
Revenue Growth (YoY)7.5%
Return on Equity15.3%
Return on Assets6.2%

Balance Sheet

Cash & Equivalents$540.00M
Total Debt$12.62B
Net Position$12.09B (net debt)
Free Cash Flow (TTM)$2.45B
Debt / Equity50.15

Share Ownership

Institutions 94.7%
Insiders 0.3%
Public 5.0%

Related Stocks

LLYUNHJNJMRKABBVTMOPFEISRG

Frequently Asked Questions

What does Boston Scientific Corporation (BSX) do?
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGl…
What is BSX's market cap?
Boston Scientific Corporation has a market capitalization of approximately $64.66B.
What is BSX's P/E ratio?
Boston Scientific Corporation trades at a trailing P/E ratio of 18.2x and a forward P/E of 13.1x, which is below the broad market average of ~25x.
How much revenue does BSX generate?
Boston Scientific Corporation generated $21.00B in trailing 12-month revenue.
What do analysts say about BSX?
The analyst consensus rating for Boston Scientific Corporation is buy, with a mean price target of $61.00. That implies +36.7% upside from the current price.
When does BSX report earnings?
Boston Scientific Corporation is next scheduled to report earnings on 28 Oct 2026.
Does BSX pay a dividend?
Boston Scientific Corporation does not currently pay a regular dividend.

View live charts, options flow, gamma exposure, earnings history, and technical analysis for Boston Scientific Corporation on Apsis Markets.

Open Live Dashboard →